Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

GLP-1-based diabetes therapies; trial by media.

Hitman GA, Leslie RD, Holt RI.

Diabet Med. 2013 Oct;30(10):1147. doi: 10.1111/dme.12299. No abstract available.

PMID:
24073724
2.

Targeting the incretin system in type 2 diabetes mellitus.

Potenza M, Rayfield EJ.

Mt Sinai J Med. 2009 Jun;76(3):244-56. doi: 10.1002/msj.20112. Review.

PMID:
19421968
3.
4.

Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.

Cornell S.

J Clin Pharm Ther. 2012 Oct;37(5):510-24. doi: 10.1111/j.1365-2710.2012.01342.x. Epub 2012 Mar 21. Review.

PMID:
22436069
5.

European drugs agency clashes with scientists over safety of GLP-1 drugs.

Cohen D.

BMJ. 2013 Jul 30;347:f4838. doi: 10.1136/bmj.f4838. No abstract available.

PMID:
23900829
6.

Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects.

Drab SR.

Pharmacotherapy. 2010 Jun;30(6):609-24. doi: 10.1592/phco.30.6.609. Review.

PMID:
20500049
7.

Report all increases in serum amylase in patients starting incretins.

Lengyel Z.

BMJ. 2013 Sep 5;347:f5333. doi: 10.1136/bmj.f5333. No abstract available.

PMID:
24009264
8.

Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.

Jellinger PS.

Postgrad Med. 2011 Jan;123(1):53-65. doi: 10.3810/pgm.2011.01.2245. Review.

PMID:
21293084
9.

The future of incretin-based therapy: novel avenues--novel targets.

Ahrén B.

Diabetes Obes Metab. 2011 Oct;13 Suppl 1:158-66. doi: 10.1111/j.1463-1326.2011.01457.x. Review.

PMID:
21824270
10.

Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies.

Campbell RK, Cobble ME, Reid TS, Shomali ME.

J Fam Pract. 2010 Sep;59(9 Suppl 1):S20-7.

PMID:
20824236
11.

Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes.

van Genugten RE, Möller-Goede DL, van Raalte DH, Diamant M.

Diabetes Obes Metab. 2013 Jul;15(7):593-606. doi: 10.1111/dom.12050. Epub 2013 Jan 21. Review.

PMID:
23216746
12.

The incretins: from the concept to their use in the treatment of type 2 diabetes. Part A: incretins: concept and physiological functions.

Girard J.

Diabetes Metab. 2008 Dec;34(6 Pt 1):550-9. doi: 10.1016/j.diabet.2008.09.001. Epub 2008 Nov 25. Review.

PMID:
19036624
13.

Impact of GLP-1 and GLP-1 receptor agonists on cardiovascular risk factors in type 2 diabetes.

Verge D, López X.

Curr Diabetes Rev. 2010 Jul;6(4):191-200. Review.

PMID:
20380625
14.

Incretins and pancreatitis--what happens next? A personal viewpoint.

Robson J.

Diabet Med. 2013 Oct;30(10):1156-9. doi: 10.1111/dme.12300. No abstract available.

PMID:
24073726
15.

GLP-1 receptor agonists: effects on cardiovascular risk reduction.

Lorber D.

Cardiovasc Ther. 2013 Aug;31(4):238-49. doi: 10.1111/1755-5922.12000. Review.

PMID:
23865382
16.

The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review.

Aroda VR, Ratner R.

Diabetes Metab Res Rev. 2011 Sep;27(6):528-42. doi: 10.1002/dmrr.1202. Review.

PMID:
21484979
17.

[Innovations in the treatment of type 2 diabetes mellitus: use of incretins].

Dedov II, Shestakova MV, Sukhareva OIu.

Ter Arkh. 2010;82(10):5-10. Russian.

PMID:
21341455
18.

Incretin-based therapies: review of current clinical trial data.

Peters A.

Am J Med. 2010 Mar;123(3 Suppl):S28-37. doi: 10.1016/j.amjmed.2009.12.007. Review.

PMID:
20206729
19.

The multifaceted potential of glucagon-like peptide-1 as a therapeutic agent.

Lam NT, Kieffer TJ.

Minerva Endocrinol. 2002 Jun;27(2):79-93. Review.

PMID:
11961501
20.

Incretin-based therapies in the treatment of type 2 diabetes--more than meets the eye?

Labuzek K, Kozłowski M, Szkudłapski D, Sikorska P, Kozłowska M, Okopień B.

Eur J Intern Med. 2013 Apr;24(3):207-12. doi: 10.1016/j.ejim.2013.01.009. Epub 2013 Jan 31. Review.

PMID:
23375875

Supplemental Content

Support Center